Delcath Systems (DCTH) Stock Forecast & Price Target

Delcath Systems is benefiting from strong commercial execution, with 2Q26 revenue of $29.1M beating consensus and Hepzato KIT sales of $27.1M, while volume rose 30% year over year despite some ASP pressure from 340B pricing. Management also raised FY2026 revenue guidance to $104M-$108M, expects gross margins of 86%-89%, and continues to guide for positive adjusted EBITDA, supported by better-than-expected efficiency and about $6M in operating cash flow. The outlook is further strengthened by a growing network of 31 active treatment centers, roughly 80% NCI Comprehensive designation, and a path to 37 centers by year-end, which should support continued volume gains and broader adoption.

Delcath Systems is vulnerable to the pace of U.S. commercialization, pricing and reimbursement friction, and competitive and supply-chain pressures that could slow Hepzato adoption despite recent traction. Although 2Q26 revenue reached $29.1M and exceeded consensus of $26.3M, the business still projected 2026 revenue of $106.1M alongside a net loss of $0.17 per diluted share, underscoring that profitability remains fragile. Even with approximately $96M in cash and short-term equivalents, the company’s dependence on one product platform, plus ongoing clinical and regulatory execution risks, supports a cautious fundamental view.